Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 22
2003 29
2004 32
2005 22
2006 17
2007 23
2008 20
2009 41
2010 31
2011 33
2012 41
2013 32
2014 32
2015 38
2016 34
2017 34
2018 28
2019 37
2020 37
2021 40
2022 33
2023 26
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

608 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Bakris GL, et al. Among authors: haller h. JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081. JAMA. 2015. PMID: 26325557 Clinical Trial.
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H, Górriz JL, Greene T, Haller H, Hou FF, Kang SW, Isidto R, Khullar D, Mark PB, McMurray JJV, Kashihara N, Nowicki M, Persson F, Correa-Rotter R, Rossing P, Toto RD, Umanath K, Van Bui P, Wittmann I, Lindberg M, Sjöström CD, Langkilde AM, Heerspink HJL. Wheeler DC, et al. Among authors: haller h. Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711. doi: 10.1093/ndt/gfaa234. Nephrol Dial Transplant. 2020. PMID: 32862232 Free PMC article. Clinical Trial.
[Nephrology: an update].
Haller H. Haller H. Inn Med (Heidelb). 2023 Mar;64(3):217-218. doi: 10.1007/s00108-023-01492-3. Epub 2023 Feb 20. Inn Med (Heidelb). 2023. PMID: 36807713 German. No abstract available.
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.
Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder RE, Anker SD, Filippatos G, Pitt B, Rossing P, Lambelet M, Nowack C, Kolkhof P, Joseph A, Bakris GL. Agarwal R, et al. Among authors: haller h. J Hypertens. 2023 Feb 1;41(2):295-302. doi: 10.1097/HJH.0000000000003330. Epub 2022 Dec 8. J Hypertens. 2023. PMID: 36583355 Free PMC article. Clinical Trial.
Loss of vascular endothelial notch signaling promotes spontaneous formation of tertiary lymphoid structures.
Fleig S, Kapanadze T, Bernier-Latmani J, Lill JK, Wyss T, Gamrekelashvili J, Kijas D, Liu B, Hüsing AM, Bovay E, Jirmo AC, Halle S, Ricke-Hoch M, Adams RH, Engel DR, von Vietinghoff S, Förster R, Hilfiker-Kleiner D, Haller H, Petrova TV, Limbourg FP. Fleig S, et al. Among authors: haller h. Nat Commun. 2022 Apr 19;13(1):2022. doi: 10.1038/s41467-022-29701-x. Nat Commun. 2022. PMID: 35440634 Free PMC article.
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study.
Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, Banerjee A, Thuresson M, Okami S, Garal-Pantaler E, Overbeek J, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T. Birkeland KI, et al. Among authors: haller h. Diabetes Obes Metab. 2020 Sep;22(9):1607-1618. doi: 10.1111/dom.14074. Epub 2020 Jun 3. Diabetes Obes Metab. 2020. PMID: 32363737 Free PMC article.
[What is proven in treatment?].
Haller H, Schmidt-Ott K. Haller H, et al. Inn Med (Heidelb). 2023 Dec;64(12):1133-1134. doi: 10.1007/s00108-023-01633-8. Epub 2023 Nov 23. Inn Med (Heidelb). 2023. PMID: 37994933 German. No abstract available.
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Among authors: haller h. Kidney Int. 2020 Jun;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035. Epub 2020 Mar 6. Kidney Int. 2020. PMID: 32299680 Free article. Clinical Trial.
608 results